126 related articles for article (PubMed ID: 27128834)
1. A Phase I cardiac safety and pharmacokinetic study of tivozanib hydrochloride in patients with advanced solid tumors.
Moore K; Infante JR; Cotreau MM; Wilson L; Strahs AL; Vargo DL; Chadha M
Clin Pharmacol Drug Dev; 2014 Jul; 3(4):284-9. PubMed ID: 27128834
[TBL] [Abstract][Full Text] [Related]
2. Effects of ketoconazole or rifampin on the pharmacokinetics of tivozanib hydrochloride, a vascular endothelial growth factor receptor tyrosine kinase inhibitor.
Cotreau MM; Siebers NM; Miller J; Strahs AL; Slichenmyer W
Clin Pharmacol Drug Dev; 2015 Mar; 4(2):137-42. PubMed ID: 27128217
[TBL] [Abstract][Full Text] [Related]
3. Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors.
Eskens FA; de Jonge MJ; Bhargava P; Isoe T; Cotreau MM; Esteves B; Hayashi K; Burger H; Thomeer M; van Doorn L; Verweij J
Clin Cancer Res; 2011 Nov; 17(22):7156-63. PubMed ID: 21976547
[TBL] [Abstract][Full Text] [Related]
4. A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer.
Mayer EL; Scheulen ME; Beckman J; Richly H; Duarte A; Cotreau MM; Strahs AL; Agarwal S; Steelman L; Winer EP; Dickler MN
Breast Cancer Res Treat; 2013 Jul; 140(2):331-9. PubMed ID: 23868188
[TBL] [Abstract][Full Text] [Related]
5. Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study.
Hulhoven R; Rosillon D; Bridson WE; Meeus MA; Salas E; Stockis A
Clin Ther; 2008 Feb; 30(2):260-70. PubMed ID: 18343264
[TBL] [Abstract][Full Text] [Related]
6. Tivozanib, a pan-VEGFR tyrosine kinase inhibitor for the potential treatment of solid tumors.
De Luca A; Normanno N
IDrugs; 2010 Sep; 13(9):636-45. PubMed ID: 20799147
[TBL] [Abstract][Full Text] [Related]
7. Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma.
Hong DS; Kurzrock R; Wheler JJ; Naing A; Falchook GS; Fu S; Kim KB; Davies MA; Nguyen LM; George GC; Xu L; Shumaker R; Ren M; Mink J; Bedell C; Andresen C; Sachdev P; O'Brien JP; Nemunaitis J
Clin Cancer Res; 2015 Nov; 21(21):4801-10. PubMed ID: 26169970
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of highly selective inhibitor of VEGFR tyrosine kinase, tivozanib, in Japanese patients with solid tumors.
Niwakawa M; Yamaguchi R; Onozawa Y; Yasui H; Taku K; Naito T; Akinaga S; Boku N; Yamamoto N
Cancer Sci; 2013 Aug; 104(8):1039-44. PubMed ID: 23679664
[TBL] [Abstract][Full Text] [Related]
9. Tivozanib: status of development.
Jamil MO; Hathaway A; Mehta A
Curr Oncol Rep; 2015 Jun; 17(6):24. PubMed ID: 25895472
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma.
Nosov DA; Esteves B; Lipatov ON; Lyulko AA; Anischenko AA; Chacko RT; Doval DC; Strahs A; Slichenmyer WJ; Bhargava P
J Clin Oncol; 2012 May; 30(14):1678-85. PubMed ID: 22493422
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind, placebo-controlled study to evaluate the effect of repeated oral doses of pazopanib on cardiac conduction in patients with solid tumors.
Heath EI; Infante J; Lewis LD; Luu T; Stephenson J; Tan AR; Kasubhai S; LoRusso P; Ma B; Suttle AB; Kleha JF; Ball HA; Dar MM
Cancer Chemother Pharmacol; 2013 Mar; 71(3):565-73. PubMed ID: 23344712
[TBL] [Abstract][Full Text] [Related]
12. Tivozanib, a highly potent and selective inhibitor of VEGF receptor tyrosine kinases, for the treatment of metastatic renal cell carcinoma.
Jacob A; Shook J; Hutson TE
Future Oncol; 2020 Oct; 16(28):2147-2164. PubMed ID: 32692256
[TBL] [Abstract][Full Text] [Related]
13. Model-based treatment optimization of a novel VEGFR inhibitor.
Keizer RJ; Gupta A; Shumaker R; Beijnen JH; Schellens JH; Huitema AD
Br J Clin Pharmacol; 2012 Aug; 74(2):315-26. PubMed ID: 22295876
[TBL] [Abstract][Full Text] [Related]
14. A phase Ib study of the VEGF receptor tyrosine kinase inhibitor tivozanib and modified FOLFOX-6 in patients with advanced gastrointestinal malignancies.
Oldenhuis CN; Loos WJ; Esteves B; van Doorn L; Cotreau MM; Strahs AL; den Hollander MW; Gietema JA; de Vries EG; Eskens FA
Clin Colorectal Cancer; 2015 Mar; 14(1):18-24.e1. PubMed ID: 25591799
[TBL] [Abstract][Full Text] [Related]
15. The role of tivozanib in advanced renal cell carcinoma therapy.
Escudier B; Porta C; Eisen T; Belsey J; Gibson D; Morgan J; Motzer R
Expert Rev Anticancer Ther; 2018 Nov; 18(11):1113-1124. PubMed ID: 30084668
[TBL] [Abstract][Full Text] [Related]
16. BATON-CRC: A Phase II Randomized Trial Comparing Tivozanib Plus mFOLFOX6 with Bevacizumab Plus mFOLFOX6 in Stage IV Metastatic Colorectal Cancer.
Benson AB; Kiss I; Bridgewater J; Eskens FA; Sasse C; Vossen S; Chen J; Van Sant C; Ball HA; Keating A; Krivoshik A
Clin Cancer Res; 2016 Oct; 22(20):5058-5067. PubMed ID: 27401244
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the Potential for QTc Prolongation With Repeated Oral Doses of Fedratinib in Patients With Advanced Solid Tumors.
Ogasawara K; Xu C; Yin J; Darpo B; Carayannopoulos L; Xue H; Palmisano M; Krishna G
Clin Pharmacol Drug Dev; 2021 Apr; 10(4):366-375. PubMed ID: 32673446
[TBL] [Abstract][Full Text] [Related]
18. Phase 1 study to evaluate the effect of the MEK inhibitor trametinib on cardiac repolarization in patients with solid tumours.
Patnaik A; Tolcher A; Papadopoulos KP; Beeram M; Rasco D; Werner TL; Bauman JW; Scheuber A; Cox DS; Patel BR; Zhou Y; Hamid M; Schramek D; Sharma S
Cancer Chemother Pharmacol; 2016 Sep; 78(3):491-500. PubMed ID: 27392790
[TBL] [Abstract][Full Text] [Related]
19. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
Eskens FA; Steeghs N; Verweij J; Bloem JL; Christensen O; van Doorn L; Ouwerkerk J; de Jonge MJ; Nortier JW; Kraetzschmar J; Rajagopalan P; Gelderblom H
J Clin Oncol; 2009 Sep; 27(25):4169-76. PubMed ID: 19636022
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the effects of bitopertin (RG1678) on cardiac repolarization: a thorough corrected QT study in healthy male volunteers.
Hofmann C; Banken L; Hahn M; Swearingen D; Nagel S; Martin-Facklam M
Clin Ther; 2012 Oct; 34(10):2061-71. PubMed ID: 22980315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
